VISCERA LABS

Viscera Labs Announces the Completion of the Preclinical Evaluation of VL-001

PARSIPPANY, NJ – February 1, 2023 – Viscera Labs, Inc. today announced that it had completed the preclinical evaluation of VL-001, its novel formulation of colesevelam that is being developed for the treatment of bile acid diarrhea.

The preclinical study program had two objectives: (1) assess the delivery of VL-001 to the terminal ileum; and (2) evaluate the efficacy of VL-001. Viscera conducted three preclinical studies in pursuit of these objectives. VL-001-P01 assessed the delivery of VL-001 to the gastric tract, VL-001-P02 assessed the efficacy of VL-001, and VL-001-P03 confirmed the efficacy of VL-001 seen in VL-001-P02. All three studies used healthy C57BL6 mice.

Published studies suggest that bile acid sequestrants may have clinical utility in bile acid-mediated conditions such as bile acid malabsorption diarrhea[1]. However, existing formulations of bile acid sequestrants are suboptimal and hence inadequate for these conditions. Viscera Labs is developing VL-001 to improve the efficacy, safety, and tolerability of colesevelam in bile acid-mediated conditions.

References

1. Beigel F, et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. J Crohns Colitis. 2014 Nov; 8(11): 1471-9.

About Viscera Labs

Viscera Labs is an innovative pharmaceutical company focused on developing novel and cost-effective therapeutic agents for bile acid-mediated disorders.